493 related articles for article (PubMed ID: 36822241)
61. Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response.
Liang R; Xie J; Li J; Wang K; Liu L; Gao Y; Hussain M; Shen G; Zhu J; Tao J
Biomaterials; 2017 Dec; 149():41-50. PubMed ID: 28992509
[TBL] [Abstract][Full Text] [Related]
62. Facile preparation of a metal-phenolic network-based lymph node targeting nanovaccine for antitumor immunotherapy.
Su Q; Liu Z; Du R; Chen X; Chen L; Fu Z; Luo X; Yang Y; Shi X
Acta Biomater; 2023 Mar; 158():510-524. PubMed ID: 36603733
[TBL] [Abstract][Full Text] [Related]
63. Nanotechnology for the Development of Nanovaccines in Cancer Immunotherapy.
Grimaudo MA
Adv Exp Med Biol; 2021; 1295():303-315. PubMed ID: 33543465
[TBL] [Abstract][Full Text] [Related]
64. Efficient Nanovaccine Delivery in Cancer Immunotherapy.
Zhu G; Zhang F; Ni Q; Niu G; Chen X
ACS Nano; 2017 Mar; 11(3):2387-2392. PubMed ID: 28277646
[TBL] [Abstract][Full Text] [Related]
65. Hydrogel-guided strategies to stimulate an effective immune response for vaccine-based cancer immunotherapy.
Lei L; Huang D; Gao H; He B; Cao J; Peppas NA
Sci Adv; 2022 Nov; 8(47):eadc8738. PubMed ID: 36427310
[TBL] [Abstract][Full Text] [Related]
66. The application of exosomes as a nanoscale cancer vaccine.
Tan A; De La Peña H; Seifalian AM
Int J Nanomedicine; 2010 Nov; 5():889-900. PubMed ID: 21116329
[TBL] [Abstract][Full Text] [Related]
67. Construction of pH-Sensitive Nanovaccines Encapsulating Tumor Cell Lysates and Immune Adjuvants for Breast Cancer Therapy.
Ding Y; Yang J; Wei H; Wang J; Huang S; Yang S; Guo Y; Li B; Shuai X
Small; 2023 Sep; 19(37):e2301420. PubMed ID: 37154213
[TBL] [Abstract][Full Text] [Related]
68. The potential of mRNA vaccines in cancer nanomedicine and immunotherapy.
Pan S; Fan R; Han B; Tong A; Guo G
Trends Immunol; 2024 Jan; 45(1):20-31. PubMed ID: 38142147
[TBL] [Abstract][Full Text] [Related]
69. Instigation of the epoch of nanovaccines in cancer immunotherapy.
Shah S; Famta P; Tiwari V; Kotha AK; Kashikar R; Chougule MB; Chung YH; Steinmetz NF; Uddin M; Singh SB; Srivastava S
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(3):e1870. PubMed ID: 36410742
[TBL] [Abstract][Full Text] [Related]
70. Cancer Immunotherapy of TLR4 Agonist-Antigen Constructs Enhanced with Pathogen-Mimicking Magnetite Nanoparticles and Checkpoint Blockade of PD-L1.
Traini G; Ruiz-de-Angulo A; Blanco-Canosa JB; Zamacola Bascarán K; Molinaro A; Silipo A; Escors D; Mareque-Rivas JC
Small; 2019 Jan; 15(4):e1803993. PubMed ID: 30569516
[TBL] [Abstract][Full Text] [Related]
71. Nucleic Acid Nanoparticles at a Crossroads of Vaccines and Immunotherapies.
Dobrovolskaia MA
Molecules; 2019 Dec; 24(24):. PubMed ID: 31861154
[TBL] [Abstract][Full Text] [Related]
72. Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences.
Chung CK; Da Silva CG; Kralisch D; Chan A; Ossendorp F; Cruz LJ
J Control Release; 2018 Sep; 285():56-66. PubMed ID: 30008371
[TBL] [Abstract][Full Text] [Related]
73. Multifunctional nanoparticles for cancer immunotherapy.
Saleh T; Shojaosadati SA
Hum Vaccin Immunother; 2016 Jul; 12(7):1863-75. PubMed ID: 26901287
[TBL] [Abstract][Full Text] [Related]
74. A Designer Scaffold with Immune Nanoconverters for Reverting Immunosuppression and Enhancing Immune Checkpoint Blockade Therapy.
Phuengkham H; Song C; Lim YT
Adv Mater; 2019 Oct; 31(42):e1903242. PubMed ID: 31490604
[TBL] [Abstract][Full Text] [Related]
75. At the bench: Engineering the next generation of cancer vaccines.
Shae D; Baljon JJ; Wehbe M; Becker KW; Sheehy TL; Wilson JT
J Leukoc Biol; 2020 Oct; 108(4):1435-1453. PubMed ID: 31430398
[TBL] [Abstract][Full Text] [Related]
76. Gold nanoparticle mediated cancer immunotherapy.
Almeida JP; Figueroa ER; Drezek RA
Nanomedicine; 2014 Apr; 10(3):503-14. PubMed ID: 24103304
[TBL] [Abstract][Full Text] [Related]
77. Progress in Vaccine Therapies for Breast Cancer.
Li X; Bu X
Adv Exp Med Biol; 2017; 1026():315-330. PubMed ID: 29282691
[TBL] [Abstract][Full Text] [Related]
78. In Situ Tumor Vaccine for Lymph Nodes Delivery and Cancer Therapy Based on Small Size Nanoadjuvant.
Zhang H; Zhang Y; Hu H; Yang W; Xia X; Lei L; Lin R; Li J; Li Y; Gao H
Small; 2023 Aug; 19(33):e2301041. PubMed ID: 37078903
[TBL] [Abstract][Full Text] [Related]
79. A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists.
Baljon JJ; Kwiatkowski AJ; Pagendarm HM; Stone PT; Kumar A; Bharti V; Schulman JA; Becker KW; Roth EW; Christov PP; Joyce S; Wilson JT
ACS Nano; 2024 Mar; 18(9):6845-6862. PubMed ID: 38386282
[TBL] [Abstract][Full Text] [Related]
80. Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity.
Kroll AV; Fang RH; Jiang Y; Zhou J; Wei X; Yu CL; Gao J; Luk BT; Dehaini D; Gao W; Zhang L
Adv Mater; 2017 Dec; 29(47):. PubMed ID: 29239517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
